WO2009046346A3 - Stem cell therapy for weight loss - Google Patents

Stem cell therapy for weight loss Download PDF

Info

Publication number
WO2009046346A3
WO2009046346A3 PCT/US2008/078813 US2008078813W WO2009046346A3 WO 2009046346 A3 WO2009046346 A3 WO 2009046346A3 US 2008078813 W US2008078813 W US 2008078813W WO 2009046346 A3 WO2009046346 A3 WO 2009046346A3
Authority
WO
WIPO (PCT)
Prior art keywords
weight loss
stem cell
cell therapy
weight
order
Prior art date
Application number
PCT/US2008/078813
Other languages
French (fr)
Other versions
WO2009046346A8 (en
WO2009046346A2 (en
Inventor
Neil H. Riordan
Thomas E. Ichim
Original Assignee
Medistem Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medistem Laboratories, Inc. filed Critical Medistem Laboratories, Inc.
Publication of WO2009046346A2 publication Critical patent/WO2009046346A2/en
Publication of WO2009046346A8 publication Critical patent/WO2009046346A8/en
Publication of WO2009046346A3 publication Critical patent/WO2009046346A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are methods, cells, and compositions of matter useful for the treatment of obesity, including but not limited to, diminishment of rate of weight gain, maintenance of body weight, or induction of weight loss. The invention teaches particular administration of various cell populations, including mononuclear cells from adipose tissue, in order to directly induce weight loss or activate biological pathways whose effects culminate in weight loss. The invention may also be utilized within the context of existing weight loss programs in order to augment their efficacy.
PCT/US2008/078813 2007-10-04 2008-10-03 Stem cell therapy for weight loss WO2009046346A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97760707P 2007-10-04 2007-10-04
US60/977,607 2007-10-04

Publications (3)

Publication Number Publication Date
WO2009046346A2 WO2009046346A2 (en) 2009-04-09
WO2009046346A8 WO2009046346A8 (en) 2009-06-04
WO2009046346A3 true WO2009046346A3 (en) 2011-07-07

Family

ID=40526968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/078813 WO2009046346A2 (en) 2007-10-04 2008-10-03 Stem cell therapy for weight loss

Country Status (1)

Country Link
WO (1) WO2009046346A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240052847A (en) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 Improved cell composition and methods of making the same
RU2562154C2 (en) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Amniotic adhesive cells
CN113559126A (en) 2011-06-01 2021-10-29 人类起源公司 Treatment of pain using placental stem cells
WO2014053906A2 (en) 2012-10-05 2014-04-10 Yeditepe Universitesi The application of stem cells in the orthodontic maxillary expansion
KR101789475B1 (en) 2017-09-21 2017-10-25 이화여자대학교 산학협력단 A composition for preventing or treating of osteoporosis comprising tonsil-derived mesenchymal stem cell or conditioned medium thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US6387369B1 (en) 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6316247B1 (en) 1999-06-15 2001-11-13 University Of Pittsburgh System and method for refining liposuctioned adipose tissue
WO2005017117A2 (en) 2003-08-14 2005-02-24 Martin Haas Multipotent amniotic fetal stem cells (mafsc) and banking of same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ENDE N ET AL: "Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 321, no. 1, 13 August 2004 (2004-08-13), pages 168 - 171, XP004521413, ISSN: 0006-291X, DOI: DOI:10.1016/J.BBRC.2004.06.121 *
HERNÁNDEZ P ET AL: "Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation.", ATHEROSCLEROSIS OCT 2007 LNKD- PUBMED:16982058, vol. 194, no. 2, 18 September 2006 (2006-09-18), pages E52 - E56, XP022288415, ISSN: 1879-1484 *
REHMAN JALEES ET AL: "Angiogenic potential of subcutaneous adipose stromal cells for autologous cell therapy.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 41, no. 6 Supplement A, 19 March 2003 (2003-03-19), & 52ND ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY; CHICAGO, IL, USA; MARCH 30-APRIL 02, 2003, pages 308A, XP002636569, ISSN: 0735-1097 *
TRAN THIEN T ET AL: "Transplantation of adipose tissue and stem cells: role in metabolism and disease.", NATURE REVIEWS. ENDOCRINOLOGY APR 2010 LNKD- PUBMED:20195269, vol. 6, no. 4, April 2010 (2010-04-01), pages 195 - 213, XP002636571, ISSN: 1759-5037 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules

Also Published As

Publication number Publication date
WO2009046346A8 (en) 2009-06-04
WO2009046346A2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
IL260117A (en) Treatment of diseases, disorders or conditions of the lung using placental cells
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
EP2586470A3 (en) Devices and methods for treatment of damaged tissue
WO2010083170A3 (en) Cell stimulation using quantum dots
MX2018008440A (en) Gene therapy vectors and cytosine deaminases.
WO2009046346A3 (en) Stem cell therapy for weight loss
EP2365816A4 (en) Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
WO2009031040A3 (en) Compounds with anti-cancer activity
WO2012008860A3 (en) Bacterial nitroreductase enzymes and methods relating thereto
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
EP2294183A4 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2009100137A3 (en) Magnetic cells for localizing delivery and tissue repair
ZA201304418B (en) Compositions and methods for using cells to treat heart tissue
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2013002381A (en) Bone marrow derived cd271 precursor cells for cardiac repair.
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
GB201001602D0 (en) Oligopeptidic compounds and uses therof
WO2012047951A3 (en) Human lung stem cells and uses thereof
WO2010132622A3 (en) Anticd20-cpg conjugates and methods of treating b cell malignancies
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
EP2086333A4 (en) Isolated myeloid-like cell populations and methods of treatment therewith
WO2012019086A3 (en) Inhibition of lar phosphatase to enhance therapeutic angiogenesis
BRPI0914473A2 (en) "Prostate and prostate cancer stem cells, methods of isolating a prostate stem cell and selection of a prostate cancer patient, and methods to inhibit proliferation of a prostate stem cell, for the prevention of prostate cancer relapse, for prostate cancer treatment, for providing adjuvant therapy, for promoting growth or repair of prostate tissue, for promoting prostate growth, for functional prostate delivery, and for selecting a compound "

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834794

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 112 (1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 08834794

Country of ref document: EP

Kind code of ref document: A2